Discuss the strategic importance of indigenising bulk drug (API) manufacturing. What are the bottlenecks?

Bulk drugs — Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) — are the chemical core of every formulation. India, the "Pharmacy of the World", still imports a high share of these inputs, largely from a single source country, making indigenisation a question of health security, not merely industrial policy [1].

Strategic importance

• Supply-chain resilience: COVID-19 border closures exposed the risk of single-source dependence. The PLI scheme for KSMs/DIs/APIs (2020, ₹6,940 crore outlay) targets 41 identified bulk drugs with the highest import dependence [3], and has already enabled import avoidance worth ₹3,591 crore [4].
• Affordability and Right to Health: cheap domestic APIs are the input base for generics sold through Jan Aushadhi Kendras, which grew from 84 (2014) to 19,200+ (2026) and saved citizens over ₹40,000 crore [1].
• Economic depth: Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh, with ₹1,000 crore central assistance each, provide subsidised power, water and effluent treatment to cluster API units [2]. PLI-Pharma has drawn ₹42,694 crore investment and 1.13 lakh+ jobs [1].
• Diplomatic leverage: secure API supply sustains India's vaccine and generic exports to 200+ countries [1].

Bottlenecks

• Cost disadvantage: competitors enjoy larger scale and subsidised utilities; Indian API costs remain structurally higher.
• Technology gap: limited capability in fermentation-based APIs, which are capital- and energy-intensive.
• Environmental burden: API manufacture is effluent-heavy; clearances and ETP costs delay projects — the very gap common infrastructure in parks seeks to close [2].
• Implementation lags: land acquisition and utility creation in parks progress slowly.
• Regulatory fragmentation: CDSCO regulates quality, NPPA caps prices under DPCO 2013, DoP runs schemes — with price ceilings compressing margins on low-value APIs.
• Thin R&D base, keeping India dependent on imported process technology.

Indigenisation is thus both a resilience shield and a growth engine. A calibrated path — sustaining PLI beyond its tenure, fast-tracking park infrastructure, incentivising green chemistry and fermentation R&D, and harmonising price control with viability — can convert India's formulation strength into genuine value-chain self-reliance, anchoring Atmanirbhar Bharat in SDG-3's promise of affordable health for all.